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 Obstructive sleep apnoea is a major public health 
problem worldwide1-3. It is associated with several 
consequences including neurocognitive impairment4. 
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Background & objectives: Repeated apnoeic/hypoapnoeic episodes during sleep may produce cerebral 
damage in patients with obstructive sleep apnoea (OSA). The aim of this study was to determine the 
absolute concentration of cerebral metabolites in apnoeic and non-apnoeic subjects from different 
regions of the brain to monitor the regional variation of cerebral metabolites.
Methods: Absolute concentration of cerebral metabolites was determined by using early morning proton 
magnetic resonance spectroscopy (1H MRS) in 18 apnoeic patients with OSA (apnoeics) having apnoea/
hypopnoea index (AHI) >5/h, while 32 were non-apnoeic subjects with AHI< 5/h.
Results: The absolute concentration of tNAA [(N-acetylaspartate (NAA)+N-acetylaspartylglutamate 
(NAAG)] was observed to be statistically significantly lower (P<0.05) in apnoeics in the left temporal and 
left frontal gray regions compared to non-apnoeics. The Glx (glutamine, Gln + glutamate, Glu) resonance 
showed higher concentration (but not statistically significant) in the left temporal and left frontal regions 
of the brain in apnoeics compared to non-apnoeics. The absolute concentration of myo-inositol (mI) was 
significantly high (P<0.03) in apnoeics in the occipital region compared to non-apnoeics.
Interpretation & conclusions: Reduction in the absolute concentration of tNAA in apnoeics is suggestive 
of neuronal damage, probably caused by repeated apnoeic episodes in these patients. NAA showed 
negative correlation with AHI in the left frontal region, while Cho and mI were positively correlated in 
the occipital region and Glx showed positive correlation in the left temporal region of the brain. Overall, 
our results demonstrate that the variation in metabolites concentrations is not uniform across various 
regions of the brain studied in patients with OSA. Further studies with a large cohort of patients to 
substantiate these observations are required. 
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Magnetic resonance spectroscopy (MRS) is a 
non-invasive method, useful for evaluating local 
metabolic changes in various conditions affecting the 
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central nervous system, including tumours5, infarction 
and ischaemia5, multiple sclerosis, Alzheimer’s 
disease, and epilepsy. Neuropsychological6 and 
electrophysiological tests have been used to evaluate 
central nervous system impairment in patients with 
obstructive sleep apnoea (OSA). In these patients, 
repeated apnoeic episodes during sleep may lead to 
changes in cerebral metabolism. Excessive daytime 
sleepiness and cognitive and emotional deficits are 
common daytime symptoms of OSA7-9. Hypoxic brain 
damage and fragmentation of sleep are generally 
thought to be causes of these deficits10,11.  
 Several MRI studies in patients with OSA reported 
varying results. Regional gray matter loss in the frontal 
cortex, parietal cortex, temporal lobe, anterior cingulate, 
hippocampus, and cerebellum12,13 and hippocampal 
atrophy in patients with OSA have been reported14. 
However, O’Donoghue and colleagues15 found no 
evidence of gray matter change in hippocampus, 
temporal lobe, and whole brain in patients with OSA. 
 Previous MRS studies have documented cerebral 
metabolic changes in patients with OSA16-22. A decrease 
in n-acetyl aspartate/choline (NAA/Cho) in the 
periventricular white matter in patients with moderate 
to severe OSA16 and NAA/creatine (Cr) and Cho/Cr 
ratios in the frontal white matter of severe OSA patients 
compared with controls17 was reported. Recently, Tonon 
et al20 reported lowered cortical NAA in OSA patients 
compared with controls. Reduced NAA/Cho in the left 
hippocampus and right frontal cortex was also reported 
in children with OSA23.  
 Though several MRI and MRS studies on patients 
with OSA have been reported in literature; only two 
or three regions of the brain were investigated with 
varying findings. Further, only metabolite ratios were 
used instead of absolute concentration of metabolites, 
except in two studies18-20. The aim of the present study 
was, therefore, to determine the absolute concentration 
of cerebral metabolites in apnoeic (OSA) and non-
apnoeic subjects from five different regions of the brain 
with an objective to monitor the regional variation of 
cerebral metabolites in these patients.
Material & Methods
Patient selection: The investigations were conducted 
at the All India Institute of Medical Sciences Hospital, 
New Delhi, a tertiary level referral center. The study 
protocol was reviewed and approved by the research 
review committee and the Institute ethical committee. 
A written informed consent was obtained from all 
patients. Subjects attending medical inpatient and 
outpatient departments from April 2004 to October 2006 
were eligible to participate in this study. Subjects were 
taken up for study using the following criteria: subjects 
of either gender in the age group of 18-60 yr, residents 
of New Delhi and nearby areas. Patients with history 
of alcoholism, chronic anxiolytic/sedative drug use, 
associated respiratory, renal, hepatic or cardiovascular 
disease or upper respiratory tract infection within the 
past one week as well as those who were pregnant or 
critically ill were excluded.
 A detailed physical examination was carried out in 
all subjects. Blood pressure was measured in recumbent 
position in all subjects after at least five minutes of 
rest. Subjects were advised to refrain from smoking 
or ingesting caffeine during the 30 min preceding the 
blood pressure measurement. A variety of large cuff 
sizes were used where necessary to ensure that bladder 
length was at least 80 per cent of the arm circumference. 
A history of antihypertensive medication intake was 
also obtained in subjects with hypertension.
 A specialist otorhinolaryngologist blinded 
to polysomnography (PSG) findings carried out 
examination of upper airway in all subjects included in 
the study. A specific note of the following abnormalities 
was made; macroglossia, pharyngeal crowding, bulky 
uvula, retrognathia, tonsillar enlargement and deviated 
nasal septum. All subjects underwent complete blood 
count (CBC), liver and renal function tests, thyroid 
functions, lipid profile, chest radiograph and an 
electrocardiogram.
Anthropometric profile: Body weight was recorded 
(to nearest 0.5 kg) in all patients, in erect position 
without shoes and wearing only light indoor clothes, 
with an electronic scale. Total body fat, excess body 
fat and total body water were estimated by bipedal 
bioelectric impedance technique using Tanita body 
composition analyzer-TBF 300 G.S., Japan. Height 
was measured to the nearest 1 cm and body mass index 
(BMI) was calculated as body weight/height2 (kg/
m2). Neck circumference (NC) was measured at the 
level of cricothyroid membrane using a non-elastic 
measuring tape. Neck length (NL) was measured 
from occipital tubercle to the vertebra prominens. A 
height-corrected measure for NC, percentage predicted 
neck circumference (PPNC) was computed using 
the formula, PPNC = (1000 x NC)/(0.55 H+310)20,21. 
Waist circumference was measured midway between 
the lower rib cage margin and the anterior superior 
iliac spine. Hip circumference was measured at the 
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maximum circumference of the buttocks, the subject 
standing with feet placed together and waist-hip ratio 
(W-HR) was calculated. 
 Skinfold thickness was measured using Lange 
skinfold calipers (Beta Technology Inc., Santa Cruz, 
CA, USA) to the nearest 1 mm. Mid-arm circumference 
(cm) was measured at the level of mid-arm taking 
acromion process and olecranon as reference points. 
Triceps and biceps skinfold thicknesses were measured 
midway between the acromion process of scapula and 
the olecranon process. Subscapular skinfold thickness 
(SSFT) was measured at the inferior angle of scapula in 
mid-axillary line and suprailiac skinfold thickness was 
measured just above the highest point of iliac crest. All 
measurements were carried out at least 3 times and the 
mean value was recorded.
Polysomnography (PSG): The PSG was performed 
as described previously25. All subjects were asked 
to complete a questionnaire before the test. Subjects 
were asked not to sleep in the afternoon on the day 
of study and not to take alcohol anxiolytic/sedative 
drugs. They were called to the Sleep Laboratory at 
0800 h and each patient was hooked to Alice 3 infant 
and adult computerized PSG machine (Healthdyne 
Technologies, USA) by standard gold cups after 
cleansing the area of attachment by spirit followed by 
Omni prep®. Subjects were requested to go to sleep 
around 0900 h. The recording of sleep was started after 
ensuring that the impedance of recording electrodes 
was set to zero. Various parameters monitored included 
electroencephalogram (EEG), electro-oculogram 
(EOG), electrocardiogram (ECG), chin and leg 
electromyogram (EMG), nasal airflow, tracheal breath 
sounds, thoracic wall and abdominal movements, 
transcutaneous oxygen saturation, body position and 
continuous positive airway pressure (CPAP) titration, 
where required. All subjects underwent PSG for at 
least 6 h. The sleep data recorded by the computer 
were manually scored for sleep stages, apnoeas, and 
hypopnoeas. An experienced laboratory technician 
blinded to any clinical data scored all polysomnograms. 
Apnoea was defined as cessation of oro-nasal airflow 
for ≥ 10 sec. Obstructive apnoeas were scored when 
airflow was absent but respiratory efforts were present. 
Hypopnoea was defined as a discernible reduction in 
respiratory airflow during a preceding period of normal 
breathing for ≥ 10 sec accompanied by a decrease of 4 
per cent or more in oxyhaemoglobin saturation during 
sleep. Apnoea-hypopnoea index (AHI) was calculated 
based on the following formula: AHI = (total no. 
of obstructive apnoeas + total no. of hypopnoeas)/
total sleep time (h). Subjects with polysomnographic 
evidence of AHI ≥5/h were categorized as ‘apnoeics’ 
and the subjects with AHI <5/h as ‘non-apnoeics’. The 
severity of OSA was graded as mild (5-14.9), moderate 
(15-29.9) and severe (>30 events/h).
1H MRS of brain: Volume-localized 1H MR 
spectroscopy was carried at 1.5 Tesla (MAGNETOM 
SONATA/AVANTO, Siemens, Germany) using a 
phased array head coil. Prior to performing 1H MR 
spectroscopy, multislice T1-weighted images in the 
coronal and sagittal planes of the whole brain were 
acquired using a standard spin-echo pulse sequence 
[time to echo (TE)= 15 msec; time for repetition (TR)= 
520 msec; 3-5 mm slice thickness; 256x256 matrix]. 
Then T2-weighted axial images were acquired using 
the parameters TE= 90 ms; TR= 2500 ms; 3-5 mm slice 
thickness; 256 x 256 matrix. These images were then 
used to select the region of interest for performing the 
MR spectroscopy. 
 Single voxel proton MR spectra were recorded 
using the PRESS pulse sequence with the following 
parameters: TR = 2000 ms; TE = 30 ms; NS = 128. Care 
was taken to optimize the magnetic field homogeneity 
by carrying out both global and voxel shim. The line-
width after voxel shim ranged from 5 to 9 Hz depending 
on the voxel size and the region studied. Spectra were 
acquired from five different areas of the brain: namely 
from left temporal, left frontal white and gray matter, 
hippocampus and occipital regions. However, spectra 
from all these brain regions could not be recorded from 
all subjects due to long acquisition time and patient 
non co-operation. The voxel size used in various brain 
regions studied varied; 2 to 2.5 ml for the left temporal 
region; 3 to 3.4 ml for the frontal lobe; 1 to 1.2 ml for the 
hippocampal region and 3.4 ml for the occipital region. 
Absolute concentration of metabolites from 5 different 
regions of the brain was estimated by LC Model which 
allows deconvolution of spectra by using a basis set of 
reference spectra. The errors in metabolite concentration 
determined are expressed in per cent standard deviation 
(%SD) of the concentration and represent the 95 per 
cent confidence interval (95% CI) of the estimated 
concentration. Further, the concentrations of metabolites 
were included only if their %SD was within 20 per cent. 
The concentration of metabolites was expressed as milli 
moles per liter (mmol/l). 
Statistical analysis: Data were recorded on a pre-
designed data sheet and managed on an ‘Excel’ 
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spreadsheet. All entries were double checked for any 
possible feeding error. Anthropometric measurements 
and PSG findings in apnoeics and non-apnoeics 
were compared using Student’s t-test or Wilcoxon’s 
Rank sum test as appropriate. The concentrations 
of each metabolites in different regions of the brain 
were compared using one way analysis of variance 
(ANOVA). Pearson’s correlation coefficient of 
AHI with various brain metabolites was calculated. 
The significance of these correlations was assessed 
by t-test. Statistical analysis was performed using 
statistical software package STATA version 10.2 (Stata 
Corporation, Houston, Texas, USA). 
Results
 A total of 50 subjects underwent overnight 
polysomnography and had early morning 1H MRS 
of the brain. Single spectrum from each volume of 
interest (VOI) was acquired from various brain regions 
and none was excluded because of poor quality. Of 
these, apnoeic group consisted of 18 patients who had 
AHI > 5/h (female 6, male 12) while the remaining 
32 were non-apnoeic with AHI <5/h (female 11, male 
21). The mean age of apnoeics and non-apnoeics was 
48.0 ± 8.8 and 39.9 ± 10.2 yr, respectively. The apnoeic 
patients had a mean BMI of 30.0 ± 5.5 kg/m2 while 
non-apnoeic subjects had a mean BMI of 27.2 ± 5.9 kg/
m2. The waist-hip ratio and neck circumference were 
significantly higher (P<0.05) in apnoeic patients as 
compared to non apnoeics (Table I). 
Polysomnograhy (Tables I, II): The mean Epworth 
sleepiness scale (ESS) value in apnoeics (12.0 ± 5.6) 
was significantly higher (P<0.001) as compared to 
non-apnoeics (5.5 ± 4.1). The AHI was significantly 
higher (P<0.001) in apnoeics (46.7 ± 29.8 events/h) 
as compared to non-apnoeics (0.89 ± 1.3 events/h). 
Both the groups showed no significant difference 
between total sleep time and sleep efficiency. The 
minimum SaO2, SaO2<90 per cent, stage I% and slow 
wave sleep showed significant differences between 
the two groups (P<0.001). In addition, stage II% and 
REM% were also significantly different between the 
groups (P<0.05).
Brain metabolites on 1H MRS (Tables III, IV and Figs 
1-4): The most prominent signal in the proton spectra 
of brain is from NAA that appears at 2.01 ppm (Fig. 1). 
The singlet at 2.04 ppm which appeared as a shoulder to 
the NAA CH3 peak (2.01 ppm) arose from the dipeptide 
N-acetylaspartylglutamate (NAAG). At low fields, NAA 
and NAAG are not easily distinguishable26,27 and hence 
the peak around 2.01 ppm in the proton MR spectrum 
is usually referred to tNAA. Other major resonances 
were from creatine (Cr) plus phosphocreatine (PCr) 
at 3.02 ppm and Cho [also has contributions from 
phosphocholine (PC) and gylcerophosphocholine 
(GPC)] at 3.2 ppm. The multiplet resonance pattern 
around 2.2 to 2.5 ppm is due to Glx [glutamate (Glu) 
and glutamine (Gln)] and the peak at 3.54 ppm is due 
to myo-inositol (mI).  
Table I. Baseline characteristics of the study groups
Variables Non-apnoeics
(n=32)
Apnoeics
(n=18)
Age (yr) 39.9 ± 10.2 48 ± 8.8
Males (%) 21 (65.6%) 12 (66.7%)
BMI (kg/m2) 27.2 ± 5.9 30 ± 5.5
Fat (%) 29 ± 11.1 34.7 ± 10.3
TSFT (mm) 20.8 ± 8.8 21 ± 7.8
BSFT (mm) 12.8 ± 6 14 ± 5
SSFT (mm) 26.3 ± 8.2 28.6 ± 9
SIFT  (mm) 31.8 ± 7.5 31.5 ± 9
Neck circumference (cm) 33.6 ± 5 37.8 ± 5.6*
Waist-hip ratio 0.97 ± 0.06 1.03 ± 0.1*
Systolic blood pressure 
(mmHg)
129.7 ± 12.4 141.4 ± 18.9*
Diastolic blood pressure 
(mmHg)
87.9 ± 11.2 93.4 ± 11.6*
Epworth sleepiness scale 5.5 ± 4.1 12 ± 5.6**
AHI (events/h) 0.89 ± 1.3 46.7 ± 29.8**
Data are expressed as mean ± SD or No. (%), unless otherwise 
indicated; *P<0.05, **P<0.001 compared to non-apnoeics
BMI, body mass index; AHI, apnoea hypoapnoea index; TSFT, 
triceps skin fold thickness; BSFT, biceps skin fold thickness; SSFT, 
subscapular skin fold thickness; SIFT, subiliac fold thickness
Table II. Comparison of polysomnography parameters between 
the study groups
Parameters Non-apnoeics 
(n=32)
Apnoeics
(n=18)
Baseline SaO2,(%) 97.3 ± 1.2 95.4 ± 5 
Minimum SaO2, (%) 88 ± 7.7 65.9 ± 14.8**
SaO2<90%, (%TST) 1.6 ± 4.9 32.3 ± 35.6**
Total sleep time (min) 361.6 ± 75.6 368.8 ± 64.3
Stage I (%) 14.3 ± 8 23.5 ± 6.7**
Stage II (%) 42.3 ± 16.2 56.7 ± 8.6*
Stage III & IV (SWS %) 24.9 ± 16.7 8.2 ± 4**
REM % 10.7 ± 5.4 7.1 ± 3.5*
Sleep efficiency (%) 83.7 ± 13.2 83 ± 11.9
Values are given as the mean ± SD, unless otherwise indicated; 
*P<0.05, **<0.001 compared with non-apnoeics
SaO2, arterial oxygen saturation; TST, total sleep time; REM, rapid 
eye movement; SWS, slow wave sleep
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Table III. Concentration of brain metabolites (mmol/l) measured by 1H MRS in different regions of brain in apnoeics and non-apnoeics
Metabolite Group Left hippocampus
absolute value
Left temporal Left frontal white Left frontal gray Occipital gray P
Cr+PCr Non-apnoeic 5.21 ± 0.84
(N = 13)
4.42 ± 0.48
(N = 25)
4.33 ± 0.57
(N = 3)
4.59 ± 0.36
(N = 7)
4.91 ± 0.57
(N = 8)
< 0.01
Apnoeic 4.78 ± 1.00
(N = 9)
4.17 ± 0.83
(N = 15)
5.12 ± 0.59
(N = 6)
4.68 ± 0.70
(N = 5)
5.18 ± 0.62
(N = 4)
0.08
P 0.29 0.22 0.10 0.76 0.48 ---
tNAA Non-apnoeic 6.13 ± 0.93
(N = 13)
8.53 ± 0.78
(N = 25)
7.57 ± 2.07
(N = 3)
6.80 ± 0.23
(N = 7)
7.60 ± 0.97
(N = 8)
< 0.001
Apnoeic 6.19 ± 1.22
(N = 9)
7.29 ± 2.14
(N = 15)
7.50 ± 0.69
(N = 7)
6.46 ± 0.27
(N = 5)
7.42 ± 0.76
(N = 4)
0.33
P 0.90 0.01 0.94 0.04 0.76 ---
mI Non-apnoeic 5.87 ± 0.91
(N = 12)
4.23 ± 0.82
(N = 21)
* 3.64 ± 0.38
(N = 5)
3.46 ± 0.41
(N = 8)
< 0.001
Apnoeic 5.92 ± 1.09
(N = 9)
4.26 ± 1.02
(N = 12)
* 4.52 ± 0.95
(N = 5)
4.10 ± 0.36
(N = 4)
0.001
P 0.92 0.93 --- 0.09 0.03 ---
Cho Non-apnoeic 1.84 ± 0.39
(N = 12)
1.62 ± 0.23
(N = 25)
1.87 ± 0.21
(N = 3)
1.13 ± 0.15
(N = 6)
0.92 ± 0.12
(N = 8)
< 0.001
Apnoeic 1.60 ± 0.32
(N = 8)
1.65 ± 0.26
(N = 15)
2.22 ± 0.25
(N = 5)
0.90 ± 0.56
(N = 4)
1.10 ± 0.22
(N = 4)
< 0.001
P 0.16 0.70 0.09 0.35 0.09 ---
Glx Non-apnoeic 11.46 ± 2.02
(N = 9)
6.93 ± 1.15
(N = 13)
* 9.47 ± 1.62
(N = 7)
9.48 ± 1.58
(N = 8)
< 0.001
Apnoeic 11.23 ± 0.94
(N = 6)
7.96 ± 1.21
(N = 7)
* 7.92 ± 0.86
(N = 5)
10.30 ± 1.89
(N = 4)
< 0.001
P 0.81 0.08 * 0.08 0.44
*Metabolite concentration was not calculated in these two regions. One-way ANOVA was used to compare the P values among different 
regions
tNAA; N-acetyl aspartate + NAAG; dipeptide N-acetylaspartylglutamate, Cr; Creatine, PCr; phosphocreatine Cho; Choline containing 
compound, Glx; glutamate (Glu) and glutamine (Gln); myo-inositol (mI)
Fig. 1. Proton MR spectrum from the frontal gray matter of an 
apnoeic patient. The insert shows the voxel position in the coronal 
MR image of the brain. The abbreviations shown in figure correspond 
to: NAA (N-acetyl aspartate); Cr (Creatine); PCr (phosphocreatine); 
Cho (Choline); NAAG (N-acetylaspartylglutamate); Glx [glutamate 
(Glu) and glutamine (Gln)]; mI(myo-inositol). 
Fig. 2. Proton MR spectrum from the frontal gray matter of a non-
apnoeic subject. The insert shows the voxel position in the coronal 
MR image of the brain. The abbreviations shown in figure correspond 
to: NAA (N-acetyl aspartate); Cr (Creatine); PCr (phosphocreatine); 
Cho (Choline); NAAG (N-acetylaspartylglutamate); Glx [glutamate 
(Glu) and glutamine (Gln)]; mI(myo-inositol). 
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 The concentration of tNAA [(N-acetylaspartate 
(NAA)+NAA glutamate (NAAG)] was observed to be 
significantly lower (P<0.05) in apnoeics in the left temporal 
(7.3 ± 2.1vs 8.5 ± 0.8 mmol/l) and left frontal regions (6.4 
± 0.30 vs 6.8 ± 0.23  mmol/l) compared to non-apnoeics 
(Figs 3, 4). The absolute concentration of myo-inositol 
(mI) was significantly higher (P<0.03) in apnoeics in the 
occipital region compared to non-apnoeics.
 The minimum oxygen saturation significantly 
correlated with tNAA in left temporal region (r=0.39 & 
P=0.01) and left frontal gray region (r=0.61 & P=0.04). 
The ESS also significantly correlated with Glx in left 
temporal region (r=0.46 & P=0.04) and with tNAA in 
left frontal gray region (r=0.72 & P=0.01).  
 The Glx (glutamine, Gln + glutamate, Glu) 
resonance showed higher concentration (but not 
statistically significant) in the left temporal and 
occipital regions of the brain in apnoeics compared 
to non-apnoeics. Other metabolites like Cho and Cr 
did not show any difference between the two groups 
in various regions of the brain studied. Further, the 
concentrations of brain metabolites were similar in the 
left hippocampal region between apnoeics and non-
apnoeics. The correlation of various brain metabolites 
with AHI for the different regions of the brain was also 
calculated and the results are presented in Table IV. 
Discussion
 Our results indicated that the variation of brain 
metabolites was not uniform across various regions of 
the brain in apnoeics and non-apnoeics. The absolute 
concentrations of metabolites (tNAA, Cho, Cr/PCr, 
mI, and Glx) from left hippocampus, temporal, frontal 
white and gray matter and occipital gray matter in both 
Table IV. Correlation of various metabolites with AHI in apnoeics 
and non-apnoeics from different regions of the brain
Area Metabolite N r (P)
Left hippocampus absolute 
value
Cr+PCr 22 - 0.0743 (0.74)
tNAA 22 - 0.0058 (0.98)
mI 21 0.0773 (0.74)
Cho 20 - 0.0366 (0.88)
Glx 15 0.0175 (0.95)
Left temporal
Cr+PCr 40 -0.1767 (0.28)
tNAA 40 - 0.2745 (0.09)
MI 33 0.1472 (0.41)
Cho 40 0.0375 (0.82)
Glx 20 0.5392* (0.01)
Left frontal white
Cr+PCr 9 0.5471 (0.13)
tNAA 10 0.0091 (0.98)
mI 4 0.4991 (0.50)
Cho 8 0.4852 (0.22)
Glx 3 0.2870 (0.81)
Left frontal gray
Cr+PCr 12 - 0.0126 (0.97)
tNAA 12 - 0.6908* (0.01)
MI 10 0.5188 (0.12)
Cho 10 - 0.2416 (0.50)
Glx 12 - 0.4554 (0.14)
Occipital gray
Cr+PCr 12 0.2454 (0.44)
tNAA 12 - 0.0691 (0.83)
MI 12 0.5972* (0.04)
Cho 12 0.6414* (0.02)
Glx 12 0.2814 (0.38)
tNAA; N-acetyl aspartate + NAAG; dipeptide 
N-acetylaspartylglutamate, Cr, Creatine; PCr, phosphocreatine; 
Cho, Choline containing compound; Glx, glutamate (Glu) and 
glutamine (Gln); myo-inositol (mI)
Fig. 4. Metabolite concentration of tNAA (NAA+NAAG) and Glx 
(Glu+Gln) metabolites for the left temporal region of the brain in 
apnoeics and non-apnoeics.
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Fig. 3. Metabolite concentration of tNAA (NAA+NAAG) and Glx 
(Glu+Gln) metabolites for the left frontal gray matter of the brain 
in apnoeics and non-apnoeics. 
the group of subjects were determined. In general, 
the concentrations of most metabolites were similar 
in the five brain regions studied between the two 
groups except for lower tNAA in left temporal and left 
frontal regions in apnoeics compared to non-apnoeics. 
Further, our data showed that apnoeic patients had 
higher concentration of Glx in the left temporal and 
occipital regions although values were not statistically 
significant compared to non-apnoeics. No lesion 
or signs of atrophy was observed in any of the OSA 
patients on MR images. 
 The prominent peak in proton MRS of brain is the 
acetyl resonance at 2.01 ppm that is predominantly from 
NAA. This peak also has contribution from protons of 
the dipeptide NAAG27. NAA is an acetyl donor and 
possibly as an osmoregulator of the nerve cell28 and is 
believed to be a marker of neuronal density, whereas 
NAAG is the most abundant peptide neurotransmitter in 
the human brain27. It is difficult to differentiate NAAG 
from NAA by in vivo MRS especially at low fields 
(e.g. 1.5T) due to the similarity of the structure and the 
spectral profile of these compounds and thus normally 
designated as total NAA (tNAA). NAAG is reported to 
be unevenly distributed in the brain27. NAAG has been 
reported to be abnormal in schizophrenia patients29 and 
reduced in amyotrophic lateral sclerosis (ALS)30. Thus, 
the reduction in the concentration of tNAA in apnoeics 
is suggestive of neuronal damage, probably caused by 
repeated apnoeic episodes.  
 Kamba et al have documented a decrease in NAA/
Cho in the periventricular white matter in patients 
with moderate to severe OSA16. They also reported 
cerebral hypoperfusion with a significant decrease 
in the NAA/Cho ratio in cerebral white matter in 
moderate to severe OSA compared with mild OSA and 
healthy control individuals16. We also analyzed our 
MRS data in apnoeics by categorizing them as mild, 
moderate and severe form and observed no change in 
the concentration of tNAA. This probably may be due 
to less number of patients in these three categories. A 
study involving more number of patients is required. 
Alchanatis et al18 reported both NAA/Cr and Cho/Cr 
ratios to be lower in the frontal white matter of severe 
OSA patients compared with controls. The absolute 
concentrations of NAA and Cho were also reported to 
be reduced in the frontal white matter of patients with 
OSA. NAA/Cho was found to be correlated with the 
severity of OSA in periventricular white matter but 
not in cerebral cortex17. Reduced NAA/Cho was also 
found in children with OSA compared with control 
children in the left hippocampus and right frontal 
cortex23. 
 Increase in NAA/Cr has also been reported in 
patients with OSA compared with controls from the 
left hippocampal area26. The increase was attributed 
to a decrease in hippocampal creatine-containing 
compounds rather than an increase in NAA. Authors 
also reported that lower levels of Cr containing 
compounds correlated with OSA severity and 
neurogognitive performance. Tonon et al20 recently 
reported lowered cortical NAA in OSA patients 
compared with controls and a positive correlation 
between cortical NAA and minimum nocturnal oxygen 
saturation. 
  Myo-inositol (mI) was significantly increased in 
the occipital gray matter in apnoeics in our study. The 
function of mI is not clearly understood, although it is 
believed to be an essential requirement for cell growth, 
an osmolyte, and storage for glucose28. A significant 
increase of mI/Cr ratio was reported from the temporal 
and frontal regions of brain in OSA patients by 
Sarchielli et al21. Altered levels have been associated 
with Alzheimer’s disease, hepatic encephalopathy and 
brain injury. 
 Our results also showed that apnoeic patients had 
higher concentration of Glx in the left temporal and left 
frontal regions of the brain compared to non-apnoeics, 
even though the values were not statistically significant. 
Glx resonance is composed of Glu and Gln resonances. 
Studies with more number of patients in the both the 
groups are required. Changes in other brain metabolites 
were non significant in different areas of the brain 
studied. Localized gray matter volumetric changes 
have been reported from various regions of the brain in 
patients with OSA including the frontal region and the 
magnitude approximates with age13. A unilateral loss 
in well-perfused structures was also observed in OSA 
patients suggestive of the onset of neural deficits13. The 
knowledge of the distribution of tNAA in brain thus 
may give insight on the role of cell neurochemistry.  
 It has been reported that elevated CO2 increases 
the oxygen uptake by its influence on the regulation of 
alveolar ventilation and ventilation-perfusion matching 
and facilitates oxygen delivery to the tissues and 
increases cerebral blood flow. These biological effects 
of hypercapnia may be especially important in patients 
with severe OSA32. However, studies have documented 
alterations in the NAA and Cho concentration primarily 
in the frontal lobe white matter16,22. 
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 NAA was found to be negatively correlated with 
AHI in the left frontal region, indicating that higher 
the AHI, lower is the concentration of NAA, indicating 
possible neuronal damage of the brain. Similar negative 
correlation was reported by Sarchielli et al21 between 
AHI and NAA/Cr ratio in the frontal regions of the 
brain of OSA patients. Cho and mI were positively 
correlated with AHI in occipital region of the brain 
while only Glx shows positive correlation in the left 
temporal region. The correlation of tNAA and Glx 
from different regions of the brain was also calculated 
but no significant correlation was observed.
 In conclusion, our results demonstrate that the 
variation of brain metabolites is not uniform across 
various regions of the brain studied in apnoeics and 
non-apnoeics. Reduction in the concentration of NAA 
in the left temporal and left frontal regions of the brain 
in apnoeics may be due to neuronal damage, caused 
probably by repeated apnoeic episodes. In addition, 
there is an increase of mI in the occipital region of the 
brain in apnoeics compared to non-apnoeics. Other 
metabolites did not show any significant changes 
in both the groups. Our results indicate the need for 
further systematic study on a large cohort of patients 
with varying severity (mild to severe) to understand 
the metabolic abnormalities and adaptive mechanisms 
associated with obstructive sleep apnoea.
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